Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.84 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.84 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373422 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| SCHEMBL29358831 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| SCHEMBL29378125 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Hydrochloric Acid SCHEMBL140197 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Hydrochloric Acid SCHEMBL29541686 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Water SCHEMBL21459280 | 0.90 | TGFBR1 (0.98) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Hydrochloric Acid SCHEMBL14778775 | 0.89 | TGFBR1 (0.98) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Hydrochloric Acid SCHEMBL29361019 | 0.89 | TGFBR1 (0.98) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| Hypochlorous Acid SCHEMBL26968133 | 0.87 | TGFBR1 (0.92) | TGFBR1MAPK14TDP1RIPK2ACVR1B | |
| SCHEMBL12187432 | 0.85 | TGFBR1 (0.61) | TGFBR1MAPK14TDP1RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759530-B2 | TKI permeability enhancers | CITY OF HOPE (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3039122-B1 | GENERATION OF ENDOCRINE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS USING SMALL MOLECULES | NOVO NORDISK AS (DK) | 2019-07-17 | — | — | EP | disclosed |
| US-20190083650-A1 | TKI PERMEABILITY ENHANCERS | CITY OF HOPE | 2019-03-21 | — | — | US | disclosed |
| US-20160208215-A1 | Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules | TAKARA BIO EUROPE AB (SE) | 2016-07-21 | — | — | US | disclosed |
| WO-2016081503-A1 | TKI PERMEABILITY ENHANCERS | CITY OF HOPE (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-03-14 | — | — | US | disclosed |
| US-20120122212-A1 | TGF-BETA PATHWAY INHIBITORS FOR ENHANCEMENT OF CELLULAR REPROGRAMMING OF HUMAN CELLS | IPIERIAN, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110281281-A1 | INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD | IPIERIAN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8048675-B1 | Integration-free human induced pluripotent stem cells from blood | IPIERIAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| WO-2010102267-A2 | TGF-BETA PATHWAY INHIBITORS FOR ENHANCEMENT OF CELLULAR REPROGRAMMING OF HUMAN CELLS | IPIERIAN, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759530-B2 | TKI permeability enhancers | ABL1, TK1, EGFR | TGFBR1 2423/4885MAPK14 706/4885TDP1 512/4885 |
| US-20190083650-A1 | TKI PERMEABILITY ENHANCERS | ABL1, TK1, EGFR | TGFBR1 2423/4885MAPK14 706/4885TDP1 512/4885 |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | HIPK2, HIPK3, HIPK1 | TGFBR1 2288/4885MAPK14 528/4885TDP1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.